Skip to main content

Advertisement

Table 4 Strain-specific A/Salomon Islands/3/2006 (H1N1), A/Brisbane/10/2007 (H3N2) and B/Florida/4/2006 (B/Florida) hemagglutination inhibition titers, seroconversion factor, seroconversion rate, and seroprotection rate

From: Prospective surveillance study of acute respiratory infections, influenza-like illness and seasonal influenza vaccine in a cohort of juvenile idiopathic arthritis patients

  H1N1 H3N2 B/Florida
  Day 0   Day 30 Day 0   Day 30 Day 0   Day 30
Seroprotection rate a (%)          
JIA (44) 21/43 (48.8)   44(100) 20/43 (46.5)   40(91) 20/43 (46.5)   42(95)
Healthy children# (10) 7(70)   10(100) 6(60)   8(80) 5(50)   10(100)
Seroconversion rate b (%)          
JIA    40/43(93)    32/43 (74.4)    31/40 (77.5)
Healthy children    7/7(100)    3/8 (37.5)    6/8 (75)
Seroconversion factor c          
JIA    16.5    5.2    7.2
Healthy children    9.8    3.0    4.0
  1. To meet the Committee for Proprietary Medicinal Products (CPMP) guidelines each of the vaccine antigens must meet at least one of the following criteria: seroprotection rate exceeding 70%, seroconversion rate exceeding 40%, and seroconversion factor exceeding 2.5. a Seroprotection rate: the percentage of vaccine recipients with a serum HI titres of at least 1:40 after vaccination. bSeroconversion rate: the percentage of vaccine recipients with an increase in serum HI titres by at least a factor of 4 after vaccination. c Seroconversion fator: the fold increase in serum geometric mean HI titres after vaccination.